Price
152.96
-1.05%52W Range
Market Cap
₹1,652.12 Cr
Traded: ₹0.86 Cr (0.05%) 0.0x
Free Float: ₹337.20 Cr (0.25% of FF traded)
Volume · 60D trend
55.75 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +15.0% | +22.0% | +12.0% | -- | +5.0% | Decelerating |
| Profit | +0.0% | -3.0% | -17.0% | -- | +508.0% | Stable |
| Return | -- | +0.0% | +8.0% | -14.0% | -- | Stable |
| ROE | +5.0% | +5.0% | +4.0% | -- | -- | Stable |
Quarterly Results
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 331 | 287 | 272 | 285 | 296 | 265 | 276 | 268 | 279 | 244 | 216 | 238 | 235 | 199 | 202 | 202 |
| Expenses | 290 | 258 | 242 | 244 | 255 | 244 | 242 | 235 | 234 | 205 | 174 | 185 | 192 | 173 | 169 | 165 |
| Operating Profit | 42 | 29 | 30 | 42 | 42 | 21 | 34 | 33 | 45 | 39 | 42 | 53 | 43 | 26 | 34 | 37 |
| OPM % | 13.0% | 10.0% | 11.0% | 15.0% | 14.0% | 8.0% | 12.0% | 12.0% | 16.0% | 16.0% | 20.0% | 22.0% | 18.0% | 13.0% | 16.7% | 18.4% |
| Other Income | 7 | 8 | 7 | 4 | 7 | 5 | 5 | 7 | 10 | 5 | 5 | 5 | 5 | 9 | 4 | 5 |
| Interest | 11 | 9 | 11 | 10 | 9 | 11 | 11 | 9 | 8 | 6 | 4 | 3 | 3 | 3 | 3 | 2 |
| Depreciation | 19 | 18 | 18 | 17 | 17 | 16 | 16 | 17 | 16 | 16 | 12 | 12 | 12 | 13 | 12 | 12 |
| Profit Before Tax | 20 | 10 | 9 | 19 | 23 | -1 | 12 | 14 | 30 | 22 | 31 | 43 | 33 | 19 | 24 | 29 |
| Tax % | 47.0% | -92.0% | 86.0% | 62.0% | 66.0% | 1547.0% | 124.0% | 83.0% | 52.0% | 26.0% | 38.0% | 35.0% | 37.0% | 28.0% | 35.1% | 35.8% |
| Net Profit | 10 | 18 | 1 | 7 | 8 | -12 | -3 | 2 | 15 | 16 | 19 | 28 | 21 | 14 | 15 | 18 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 1.0 | 1.7 | 0.2 | 0.8 | 0.8 | -1.0 | -0.2 | 0.3 | 1.4 | 1.5 | 1.8 | 2.5 | 1.9 | 1.3 | 1.4 | 1.7 |
| Sales Growth (YoY) | -- | 8.5% | -1.3% | 6.7% | 6.3% | 8.5% | 27.6% | 12.4% | 18.4% | 22.7% | 6.7% | 17.9% | 16.8% | 22.4% | -- | -- |
| Sales Growth (QoQ) | -- | 5.5% | -4.6% | -3.7% | 11.7% | -4.0% | 3.0% | -3.9% | 14.3% | 13.0% | -9.2% | 1.3% | 18.1% | -1.7% | 0.3% | -- |
| OP Growth (YoY) | 0.0% | 38.1% | -11.8% | 27.3% | -6.7% | -46.2% | -19.0% | -37.7% | 4.7% | 50.0% | 24.2% | 43.0% | -- | -- | -- | -- |
| OP Growth (QoQ) | 44.8% | -3.3% | -28.6% | 0.0% | 100.0% | -38.2% | 3.0% | -26.7% | 15.4% | -7.1% | -20.8% | 23.3% | 65.4% | -23.1% | -8.8% | -- |
| Profit Growth (YoY) | 21.6% | 266.2% | 197.8% | 147.5% | -43.0% | -166.4% | -109.5% | -87.7% | -24.8% | 19.4% | 24.7% | 49.8% | 3.6% | 36.0% | -11.0% | 71.0% |
| EPS Growth (YoY) | -- | 266.7% | 194.1% | 151.6% | -42.8% | -166.2% | -109.6% | -87.8% | -24.9% | 19.4% | 24.6% | 50.0% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 962.5% | -79.5% | -6.0% | 181.4% | -500.0% | -154.8% | -78.6% | -5.8% | -13.0% | -30.6% | 32.1% | 49.6% | -9.2% | -16.5% | -- |
| OP Margin | -- | 10.1% | 11.0% | 14.7% | 14.2% | 7.9% | 12.3% | 12.3% | 16.1% | 16.0% | 19.4% | 22.3% | 18.3% | 13.1% | 16.7% | 18.4% |
| Net Margin | -- | 6.3% | 0.4% | 2.5% | 2.7% | -4.5% | -1.1% | 0.8% | 5.4% | 6.6% | 8.8% | 11.8% | 8.9% | 7.0% | 7.5% | 9.1% |
| Material Cost % | -- | 15.1% | 12.6% | 12.4% | 12.9% | 13.8% | 10.0% | 9.7% | 8.9% | 6.8% | 7.0% | 5.6% | 7.9% | 6.0% | 8.1% | 7.1% |
| Employee Cost % | -- | 17.2% | 17.3% | 15.8% | 15.7% | 16.9% | 17.4% | 17.6% | 16.1% | 16.4% | 17.5% | 16.2% | 16.6% | 20.9% | 18.1% | 16.7% |
| P/S | 1.40 | 1.49 | 1.66 | 1.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 42.02 | 45.33 | 229.77 | 368.64 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 1.64 | 1.69 | 1.86 | 1.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Weblink letter to Shareholders is atttached herewith
Transcript of Earnings Call held on August 13, 2026
Newspaper advertisement - Notice of 22nd AGM & e-voting information
Resignation of Mr. Deepak Anand, CEO of Shalby Medtech Limited, a wholly-owned subsidiary (Senior Management)
BRSR Report for FY 2025-26
Annual Report FY 2025-26
Copy of Newspaper publication relating to Pre-despatch Notice of AGM
Audio Recording for Investor Con-Call for Unaudited Financials Results for QFY27
News Paper Advertisement for Unaudited Financial Results Q1FY2026-27
Investor Presentation
Grant of ESOP under Shalby Ltd Employee Stock Options Scheme-2021
Appointment of Mr. Shanay Vikram Shah as additional Director Designated as Whole-Time Director of the Company w.e.f. August 12, 2026.
Outcome of Board Meeting of Financial Results for Quarter ended June 30, 2026
Unaudited Financial Results for Quarter Ended June 30, 2026
Exercise of ESOP
The Board Meeting to be held on 05/08/2026 has been revised to 12/08/2026 The Board Meeting to be held on 05/08/2026 to consider unaudited financial results for quarter ended June 30, 2026 ....
Credit Rating
Schedule of Earnings Conferece Call on 7-Aug-2026 to discuss Q1FY2027 results
Shalby Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve unaudited financial results (standalone ....
Exercise of ESOP on 13-07-2026
Certificate u/r 74(5)
Receipt of an order of the Sole Arbitrator disposing the arbitration proceedings pursuant to withdrawal/settlement filed by the parties
Notice of Trading Window Closure
Schedule of Investor/Analyst Meet
Earnings Call transcript for conference call held on 29th May 2026 to discuss Q4 FY 2026 earnings
Audio recording of Q4 FY 2026
Newspaper Publication for Audited Financial Results for quarter and year ended March 31, 2026
Updates
Investor Presentation
Grant of ESOPs under Shalby Limited Employees Stcok Options Scheme - 2021
Outcome of Board Meeting
Earnings Conference Call scheduled on May 29, 2026 at 05:00 pm. IST to discuss Q4 FY 2026 earnings
Strike-off of Step-down subsidiary Ninegen Lifecare Pvt. Ltd.
Shalby Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve audited financial results (standalone ....
Secretarial Compliance Report for year ended March 31, 2026
Exercise of Employee Stock Options under Shalby Limited Employees Stock Options Scheme-2021
Resignation of Mr. Vijay Kishanlal Kedia as an Independent Director w.e.f. April 30, 2026
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Update on pending litigation-order passed by Statutory authority (Disclosure under reg. 30 of SEBI LODR)
Intimation of receipt pf approval for kidney transplant of Shalby Hospitals, Krishna unit-Regulation 30 SEBI LODR
Issuance of Standby Letter of Credit
Compliance Certificate u/r. 74(5) of SEBI (DP) Regulations, 2018
Closure of Trading Window pursuant to SEBI PIT Regulations, 2015
E-voting results and Scrutinizer Report on Postal Ballot Notice dated 11-02-2026
Inauguration of Oncology Department along with advanced Radiotherapy facilities at Krishna Shalby Hospital
Shalby Limited has inaugurated its oncology department along with advanced Radiotherapy facilities at Shalby Multi-specialty Hospital, Surat.
NABH Accreditation to PK Healthcare Pvt. Ltd. (Shalby Internatioal Hospitals) - Subsidiary Company
Credit of equity shares by subsidiary company on Rights Issue basis to the Company
Newspaper Publication for Postal Ballot
Q3 FY 2026 Earnings Call Transcript
Annual Reports
8Credit Ratings
6Concalls
39Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025Jun 2025
30 Jun 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Jul 2024
31 Jul 2024Jun 2024
30 Jun 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Jul 2023
31 Jul 2023May 2023
31 May 2023Jan 2023
31 Jan 2023Oct 2022
31 Oct 2022Aug 2022
31 Aug 2022Jun 2022
30 Jun 2022Feb 2022
28 Feb 2022Dec 2021
31 Dec 2021Oct 2021
31 Oct 2021Aug 2021
31 Aug 2021Jun 2021
30 Jun 2021May 2021
31 May 2021May 2021
31 May 2021May 2021
31 May 2021Jan 2021
31 Jan 2021Jan 2021
31 Jan 2021Oct 2020
31 Oct 2020Oct 2020
31 Oct 2020Sep 2020
30 Sept 2020Jun 2020
30 Jun 2020Feb 2020
29 Feb 2020Nov 2019
30 Nov 2019Jul 2019
31 Jul 2019May 2019
31 May 2019Jan 2019
31 Jan 2019Oct 2018
31 Oct 2018Aug 2018
31 Aug 2018May 2018
31 May 2018Mar 2018
31 Mar 2018Held by ETFs
2 ETFs hold SHALBY · sorted by weight
Held by Mutual Funds
2 schemes hold SHALBY · sorted by weight